Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Hitler's madcap mega-railway would have linked Berlin with India - 2Pain at the pump for Hampton Roads residents
- 3Journey through Pages: A Survey of \Plunging into Scholarly Universes\
- 4Navy-Marine Corps Relief Society provides emergency grants to families displaced by Iran war
- 5The most effective method to Decisively Plan Your Nursing Profession for the Best Compensation Results
- Investigate Business Mastercard Choices for Better Rewards and Rewards
- Looter indicted after pretending to be emergency worker at Dimona rocket crash site
- World leaders, rights groups react to COP30 climate deal
- New images reveal interstellar comet 3I/ATLAS approaching Earth
- Activists Took BMW and Mercedes to Court Over Gas Cars. It Didn’t Stick
- Iran-backed Iraqi militias attack Kurdistan over 450 times since beginning of war
- The gay hockey show no one saw coming — and everyone is suddenly obsessed with
- Vote In favor of Your Favored IT Administration
- Would you ever turn to AI for companionship? 6% of Americans say they could — or already have.
